{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T13:39:50Z","timestamp":1780580390765,"version":"3.54.1"},"reference-count":19,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2013,8,8]],"date-time":"2013-08-08T00:00:00Z","timestamp":1375920000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"NZ Ministry of Health"},{"DOI":"10.13039\/100008247","name":"University of Otago","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008247","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2013,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>The purpose of this study was to investigate the extent of exposure to varenicline during pregnancy in \u2018real\u2010life\u2019 post\u2010marketing use and follow\u2010up all pregnancy exposures to identify maternal and fetal outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a prospective observational cohort study conducted in New Zealand using intensive prescription event monitoring methods. A nationwide cohort of patients dispensed varenicline during a 4\u2010year period was established from pharmacy dispensing data. Women of reproductive age were followed up with specific questionnaires to identify exposure to varenicline during pregnancy and maternal and fetal outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Between 1 April 2007 and 31 March 2011, 23\u2009721 patients were dispensed varenicline. Pregnancy questionnaires were sent for 6882 women of reproductive age, representing 29% all patients (54% female\/unknown sex patients) in the varenicline cohort. The frequency of pregnancy exposure in women for whom a valid pregnancy questionnaire was returned was 23\/2739\u2009=\u20090.84%. For the 23 reports of pregnancy identified, exposure to varenicline was from the time of conception for 19 cases. Duration of exposure during pregnancy ranged from 1\u2009day to 16\u2009weeks. Adverse outcomes were identified in five of 17 live births: one baby had birth asphyxia and recurrent chest infections, one had gastro\u2010oesophageal reflux, one was diagnosed with ankyloglossia and two had feeding difficulties.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study suggests that approximately 1% of women of reproductive age prescribed varenicline may be exposed to this medicine during pregnancy. This could result in significant fetal exposure worldwide and indicates the need for a global pregnancy register for varenicline. Copyright \u00a9 2013 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.3489","type":"journal-article","created":{"date-parts":[[2013,8,8]],"date-time":"2013-08-08T07:18:50Z","timestamp":1375946330000},"page":"1086-1092","source":"Crossref","is-referenced-by-count":16,"title":["Exposure to the smoking cessation medicine varenicline during pregnancy: a prospective nationwide cohort study"],"prefix":"10.1002","volume":"22","author":[{"given":"Mira","family":"Harrison\u2010Woolrych","sequence":"first","affiliation":[{"name":"Intensive Medicines Monitoring Programme, New Zealand Pharmacovigilance Centre, Department of Preventive and Social Medicine University of Otago Medical School  Dunedin New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Paterson","sequence":"additional","affiliation":[{"name":"Department of Women's and Children's Health University of Otago  Dunedin New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Tan","sequence":"additional","affiliation":[{"name":"Intensive Medicines Monitoring Programme, New Zealand Pharmacovigilance Centre, Department of Preventive and Social Medicine University of Otago Medical School  Dunedin New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,8,8]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"Rodriguez\u2010ThompsonD.Smoking and pregnancy.Up\u2010To\u2010Date2012. [http:\/\/www.uptodate.com\/contents\/smoking\u2010and\u2010pregnancy]. [November 2012]."},{"key":"e_1_2_7_3_1","doi-asserted-by":"crossref","unstructured":"ACOG. Committee opinion no. 471: smoking cessation during pregnancy.Obstet Gynaecol2010;116: 1241.","DOI":"10.1097\/00006250-201011000-00054"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMct0800146"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.106.025130"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.328.7438.509"},{"key":"e_1_2_7_7_1","unstructured":"FDA.Safety review update of Chantix (varenicline) and risk of neuropsychiatric adverse events.http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm276737.htm. Accessed 31 October 2012 2012."},{"key":"e_1_2_7_8_1","unstructured":"Pfizer.Chantix product labeling.http:\/\/www.pdr.net\/drugpages\/productlabeling.aspx?mpcode=62950550#section\u20109.2. Accessed February 2012 2012."},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.15.1571"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.27.11.1550"},{"key":"e_1_2_7_11_1","unstructured":"Pfizer.New Zealand data sheet for Champix. March 2011;http:\/\/www.medsafe.govt.nz\/profs\/datasheets. Accessed June2011."},{"key":"e_1_2_7_12_1","first-page":"313","volume-title":"Pharmacovigilance","author":"Harrison\u2010Woolrych M","year":"2007"},{"issue":"1283","key":"e_1_2_7_13_1","first-page":"76","article-title":"Pharmacovigilance in New Zealand: the role of the New Zealand Pharmacovigilance Centre in facilitating safer medicines use","volume":"121","author":"Kunac DL","year":"2008","journal-title":"N Z Med J"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2003"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1258\/jrsm.100.10.465"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1479-828X.2012.01442.x"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/1753465809343712"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.2008.00852.x"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.106.025130"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/S0890-8567(09)61916-X"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.3489","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.3489","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.3489","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T19:10:09Z","timestamp":1697483409000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.3489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,8]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["10.1002\/pds.3489"],"URL":"https:\/\/doi.org\/10.1002\/pds.3489","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,8]]}}}